|
|
|
|
Department of Pharmacology, School of Medicine, Fukuoka University, Fukuoka, Japan (T.I., S.K., T.K.); Molecular Physiology, National Cardiovascular Center Research Institute, Osaka, Japan (T.I.); Research Laboratory, Senju Pharmaceutical Co. Ltd., Kobe, Japan (Y.I., K.I.); and Global Pharmacovigilance Post Marketing Surveillance Department, Senju Pharmaceutical Co. Ltd., Osaka, Japan (T.S.)
We investigated the properties and interaction domains of SN-6 [2-[4-(4-nitrobenzyloxy)benzyl]thiazolidine-4-carboxylic acid ethyl ester], a newly synthesized and selective Na+/Ca2+ exchange (NCX) inhibitor. SN-6 (0.3-30 µM) inhibited preferentially intracellular Na+-dependent 45Ca2+ uptake (i.e., the reverse mode) compared with extracellular Na+-dependent 45Ca2+ efflux (i.e., the forward mode) in NCX1-transfected fibroblasts. SN-6 was 3- to 5-fold more inhibitory to 45Ca2+ uptake in NCX1 (IC50 = 2.9 µM) than to that in NCX2 or NCX3 but not to that in NCKX2. We searched for regions that may form the SN-6 receptor by NCX1/NCX3-chimeric analyses and determined that amino acid regions 73 to 108 and 193 to 230 in NCX1 are mostly responsible for the differential drug response between NCX1 and NCX3. Further site-directed mutagenesis revealed that double substitutions of Val227 and Tyr228 in NCX1, which exist within the exchanger inhibitory peptide (XIP) region, mimicked the different drug response. In addition, F213R, G833C, and N839A mutations in NCX1 resulted in loss of drug sensitivity. Exchangers with mutated XIP regions, which display either undetectable or accelerated Na+-dependent inactivation, had markedly reduced sensitivity or hypersensitivity to SN-6, respectively. Cell ATP depletion enhanced the inhibitory potency of SN-6. Therefore, SN-6 at lower doses (IC50 = 0.63 µM) potently protected against hypoxia/reoxygenation-induced cell damage in renal tubular cells overexpressing NCX1, suggesting that this drug predominantly works under hypoxic/ischemic conditions. These properties of SN-6, which may be derived from its interaction with the XIP region, are advantageous to developing it as a new anti-ischemic drug.
Received January 21, 2004; accepted March 18, 2004.
Address correspondence to: Dr. Takahiro Iwamoto, Department of Pharmacology, School of Medicine, Fukuoka University, 7-45-1 Nanakuma Jonanku, Fukuoka 814-0180, Japan. E-mail: tiwamoto{at}cis.fukuoka-u.ac.jp
This article has been cited by other articles:
![]() |
L. Formisano, M. Saggese, A. Secondo, R. Sirabella, P. Vito, V. Valsecchi, P. Molinaro, G. Di Renzo, and L. Annunziato The Two Isoforms of the Na+/Ca2+ Exchanger, NCX1 and NCX3, Constitute Novel Additional Targets for the Prosurvival Action of Akt/Protein Kinase B Pathway Mol. Pharmacol., March 1, 2008; 73(3): 727 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ifuku, K. Farber, Y. Okuno, Y. Yamakawa, T. Miyamoto, C. Nolte, V. F. Merrino, S. Kita, T. Iwamoto, I. Komuro, et al. Bradykinin-Induced Microglial Migration Mediated by B1-Bradykinin Receptors Depends on Ca2+ Influx via Reverse-Mode Activity of the Na+/Ca2+ Exchanger J. Neurosci., November 28, 2007; 27(48): 13065 - 13073. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tortiglione, B. Picconi, I. Barone, D. Centonze, S. Rossi, C. Costa, M. Di Filippo, A. Tozzi, M. Tantucci, G. Bernardi, et al. Na+/Ca2+ Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area Stroke, May 1, 2007; 38(5): 1614 - 1620. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Iwamoto and S. Kita YM-244769, a Novel Na+/Ca2+ Exchange Inhibitor That Preferentially Inhibits NCX3, Efficiently Protects against Hypoxia/Reoxygenation-Induced SH-SY5Y Neuronal Cell Damage Mol. Pharmacol., December 1, 2006; 70(6): 2075 - 2083. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Iwamoto Vascular Na+/Ca2+ exchanger: implications for the pathogenesis and therapy of salt-dependent hypertension Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R536 - R545. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Beauge and R. DiPolo SEA-0400, a potent inhibitor of the Na+/Ca2+ exchanger, as a tool to study exchanger ionic and metabolic regulation Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1374 - C1380. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Akabas Na+/Ca2+ Exchange Inhibitors: Potential Drugs to Mitigate the Severity of Ischemic Injury Mol. Pharmacol., July 1, 2004; 66(1): 8 - 10. [Full Text] [PDF] |
||||